• Aclacinomycin A: Mechanism and Research Uses

  2026-09-04

  Aclacinomycin A, also called Aclarubicin, is an anthracycline DNA damage inducer with reported dual topoisomerase I and II inhibition. Product information reports apoptosis-associated caspase activation, proteasome chymotrypsin-like activity inhibition, and cell-line cytotoxicity values, while the cited rDNA study provides a framework for interpreting topological-stress responses: https://www.apexbt.com/aclacinomycin-a.html and https://doi.org/10.7554/eLife.91304.

• AMD-070 hydrochloride: CXCR4 Assay Workflows

  2026-09-04

  AMD-070 hydrochloride provides a soluble, selective way to interrogate CXCR4/CXCL12 biology in migration, immune-cell trafficking, hematologic, and anti-HIV research. This guide combines practical assay design with a cautious cross-domain lesson from an ischemia–reperfusion injury study.

• SERCA–ER Stress and HSC Mobilization

  2026-09-03

  Li et al. identify SERCA-mediated endoplasmic reticulum stress as a regulator of hematopoietic stem cell mobilization. Using BHQ, in vivo mobilization assays, cell-line knockdown, flow cytometry, qRT-PCR, and western blotting, the study links SERCA inhibition to the CaMKII–STAT3–CXCR4 pathway and reduced CXCR4 surface expression.

• Lypressin Acetate: Mechanism and Research Use

  2026-09-03

  Lypressin acetate, also called Lysine vasopressin acetate, is a lysine-substituted vasopressin peptide that activates V1a, V1b, and V2 receptors. Its established context is antidiuretic therapy and vasopressin research, while its SARS-CoV-2 RdRp activity remains an early translational hypothesis rather than a validated antiviral indication.

• Regorafenib Workflows for Angiogenesis Research

  2026-09-02

  Regorafenib (BAY 73-4506) supports integrated studies of kinase signaling, endothelial behavior, tumor-cell invasion, and melanoma mechanism. This practical guide connects dose-finding and migration assays with RRM2–ERK/E2F3 readouts for more interpretable cancer biology research.

• Sulfo-NHS-LC-Biotin Protocol and QC Guide

  2026-09-02

  Sulfo-NHS-LC-Biotin (SKU A8003) provides water-compatible, irreversible biotin labeling of accessible primary amines on proteins, peptides, and intact cell surfaces. It is suited to stable cell-surface protein biotinylation and streptavidin-based capture, but not to reversible modification or routine intracellular labeling.

• Sunitinib Workflows for RTK and RCC Research

  2026-09-01

  Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor for dissecting angiogenesis, tumor-cell survival, and resistance in advanced cancer models. This workflow-focused guide connects RTK pharmacology with metabolic rescue experiments, helping researchers distinguish direct pathway inhibition from glycolysis-driven treatment escape.

• ATRX Loss Increases Glioma Sensitivity to PDGFR Inhibitors

  2026-09-01

  The reference study shows that ATRX-deficient high-grade glioma cells are preferentially vulnerable to several receptor tyrosine kinase and PDGFR inhibitors, and that combining these agents with temozolomide can intensify cellular toxicity. Its main translational contribution is a genotype-aware framework for interpreting RTK inhibitor responses and designing glioma trials around ATRX status.

• NVP-BGJ398 Phosphate: FGFR1–3 Research Guide

  2026-08-31

  NVP-BGJ398 phosphate is a potent FGFR1–3 inhibitor for studying receptor-driven cancer and skeletal disease models. Its strongest evidence supports FGFR-altered cancer-cell assays and FGFR3-dependent SLC26A2 chondrodysplasia research, not clinical treatment.

• PR-619 Workflow for DUB Research

  2026-08-31

  PR-619 enables reversible, cell-permeable inhibition of multiple cysteine-dependent deubiquitinating enzymes without directly blocking proteasomal catalytic activity. This guide translates that distinction into practical workflows for ubiquitination pathway research, autophagy assays, cancer models, and carefully bounded neurodegeneration studies.

• Reactive Oxygen Species Assay Kit: Live-Cell ROS

  2026-08-30

  Learn how to use the Reactive Oxygen Species Assay Kit for controlled live-cell oxidative stress measurement, mechanism-focused treatment comparisons, and nanoparticle studies. A practical DCFH-DA workflow, control strategy, and troubleshooting guide helps distinguish a reproducible ROS-associated signal from assay interference.

• Salvianolic acid B: Designing Better Fibrosis Assays

  2026-08-29

  Salvianolic acid B, also known as Dan Shen Suan B, offers a useful way to study how LH2-dependent collagen maturation reshapes fibrotic lung models. This guide focuses on assay architecture, endpoint selection, compound handling, and the translational limits of interpreting antifibrotic responses.

• CRL3ARMC5 and Integrator Control RNA Pol II

  2026-08-28

  Cacioppo et al. identify CRL3ARMC5-mediated RNA polymerase II ubiquitylation and Integrator phosphatase activity as parallel quality-control pathways acting before productive elongation. The study shows that these mechanisms regulate both RNA Pol II abundance and transcriptional competence, providing a framework for interpreting early transcription defects and growth phenotypes after perturbation.

• miR-146a/b-5p–IRAK1–NF-κB in URSA

  2026-08-28

  A 2026 Journal of Molecular Recognition study integrates transcriptomic screening, trophoblast experiments, target validation, and a mouse model to define a miR-146a/b-5p–IRAK1–NF-κB regulatory axis in unexplained recurrent spontaneous abortion. The findings connect altered microRNA expression with trophoblast injury and pregnancy outcomes, while also outlining a testable framework for molecular validation of URSA-associated gene expression changes.

• CD36-Driven Lipid Signaling in AML Immune Escape

  2026-08-27

  This 2024 Cell Reports Medicine study identifies a non-canonical role for CD36 in acute myeloid leukemia: oxidized LDL sensing and palmitate transfer cooperate to activate innate immune signaling that suppresses T-cell activity. The work also shows that high-fat conditions and decitabine can intensify this immunosuppressive state, whereas lipid restriction with statins improves decitabine responses in experimental AML models.

7933 records 1/529 page Next 12345 下5页 Last page